With Type 1 Diabetes on the Rise, AdventHealth Study Aims to Expand Screening

The state-funded effort, known as ACCESS-T1D, is seeking children and adults who are at elevated risk.

An older man using a blood sugar measuring device

Researchers at AdventHealth are working to tackle a growing problem – the prevalence of undiagnosed type 1 diabetes (T1D) in its early stages, in particular among the state’s underserved and minority communities -- to increase access to care.

While type 2 diabetes is more prevalent, type 1 is on the rise. Type 1 diabetes can cause diabetic ketoacidosis, a potentially deadly condition that is present in up to 60% of children at the time of diagnosis when not caught early via screening. Type 1 diabetes is associated with various acute and chronic complications, including early death.

“We have improved technology and treatments, including a new medication that can delay T1D clinical onset, and we can predict that T1D will occur,” said Dr. Anna Casu, principal investigator on the study. “But the data tell us that people from ethnic and racial minority groups or people in disadvantaged communities tend to have less access to pre-clinical screening and advanced care. We are working to change that.”

Dr. Casu
Dr. Anna Casu an Associate Investigator at the AdventHealth Translational Research Institute and the principal investigator on the ACCESS TD1 study.

Funded by the state of Florida, the project is known as Access to Clinical Care, Education and Screening for Underserved Children and Adults with Type 1 Diabetes (ACCESS-T1D). In addition to increasing screening and treatment access, researchers plan to establish a biobank, which will help them to identify new and better biomarkers of T1D.

“We will bring screening opportunities physically closer to those who are at high risk of T1D, reducing their burden and facilitating participation, especially of underserved and disadvantaged populations, who often cannot take time off their work or family commitments to take care of themselves,” said Casu, who herself has T1D.

Researchers are seeking participants who meet at least one of the following criteria:

  • One or more first- or second-degree family members (siblings, parents, cousins, aunts, uncles, grandparents) diagnosed with type 1 diabetes;
  • Have other autoimmune diseases such as but not limited to celiac disease, multiple sclerosis, rheumatoid arthritis, or thyroid disease;
  • Those diagnosed with other forms of diabetes but are suspected to have T1D and have been misdiagnosed.

An awareness campaign will soon be launched about the study and screening opportunities. People interested in participating can call Call407-303-7193, Call877-854-8475 or visit TRI-MD.org.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News

AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease

While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...

News

AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)

Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...

News

AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease

Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...

News

New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy

Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...

News

AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease

Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...